Currently submitted to: JMIR Cancer
Date Submitted: Nov 26, 2025
Open Peer Review Period: Nov 27, 2025 - Jan 22, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Research Trends and Visualization Analysis of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma from 2004 to 2025: A Bibliometric Study
ABSTRACT
Background:
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally. It is often diagnosed at advanced stages or in patients unsuitable for traditional curative treatments. Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as a highly effective and non-invasive local treatment, demonstrating excellent local control rates across various HCC stages. This bibliometric study aims to comprehensively analyze the research trends, hotspots, and collaborative patterns in the field of SBRT for HCC from 2004 to 2025.
Objective:
This bibliometric study aims to comprehensively analyze the research trends, hotspots, and collaborative patterns in the field of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) from 2004 to 2025.
Methods:
Literature on SBRT for HCC published between January 1, 2004, and November 12, 2025, was retrieved from the Web of Science Core Collection (WoSCC) database. A total of 2,216 relevant publications were identified and analyzed using bibliometric software including Biblioshiny (R version 4.4.1), VOSviewer (version 1.6.17), ScimagoGraphica (version 1.0.41), CiteSpace (version 6.1. R6), and Microsoft Excel (2019 edition). The analysis covered publication output, country/region, institution, author contributions, journal distribution, co-citation patterns, and keyword trends.
Results:
A total of 2,216 publications (1,796 articles, 420 reviews) were analyzed, revealing a significant upward trend in annual publications, with a peak of over 220 in 2021. The United States and China emerged as leading countries in research output and international collaboration, with the United States also having the highest citation count. Key institutions included the University of Toronto, the University of Texas System, and Harvard University. Laura A. Dawson and Marta Scorsetti were identified as the most prolific and influential authors. The International Journal of Radiation Oncology Biology Physics was the core journal, leading in H-index and citations. Keyword analysis identified “stereotactic body radiotherapy,” “radiotherapy,” “SBRT,” and “radiofrequency ablation” (RFA) as high-frequency terms. Recent research hotspots (2023-2025) include “Y90 radioembolization,” “open-label studies,” and “motion management,” indicating a shift towards integrated and technologically advanced approaches, along with growing interest in combining SBRT with immunotherapy and targeted therapy.
Conclusions:
The field of SBRT for HCC has experienced rapid growth over the past two decades, with the United States and China at the forefront of research. SBRT has proven effective across early-stage, recurrent, and locally advanced HCC, particularly in combination with systemic therapies. Future research should prioritize large-scale randomized controlled trials (RCTs), explore SBRT’s synergy with novel immunotherapies, optimize patient selection with biomarkers, and refine advanced delivery techniques to further enhance patient outcomes and broaden its clinical application.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.